Galenica commences Tender Offer for Relypsa
August 04, 2016 00:57 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Galenica Group today announced that...
Galenica to acquire Relypsa to strengthen its Business unit Vifor Pharma
July 21, 2016 01:01 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Galenica and Relypsa announce...
Vifor Pharma expands ESA product portfolio with rights to commercialise Pfizer's proposed epoetin alfa biosimilar, Retacrit(TM), in the US dialysis market
May 24, 2016 00:59 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Vifor Pharma, a company of the...
The 2016 ESC heart failure guidelines strongly recommend Ferinject® for the treatment of iron deficiency in patients with systolic heart failure
May 23, 2016 01:31 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- Iron deficiency is confirmed as...
Vifor Pharma appoints Colin Bond as Chief Financial Officer
May 10, 2016 01:31 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Vifor Pharma today announced the...
Vifor Pharma Licenses Rights to Commercialize ChemoCentryx's Orally-Administered Complement 5aR Inhibitor CCX168 for Orphan and Rare Renal Diseases in Europe and Certain Other Major Markets
May 10, 2016 01:02 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- Vifor Pharma to market drug in...
Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter Into Agreement for OPKO's RAYALDEE(R)
May 09, 2016 01:30 ET
|
Vifor Pharma Ltd.
Vifor Fresenius Medical Care Renal Pharma obtains rights to commercialize RAYALDEE® in Europe, Canada and certain other international markets
OPKO to receive up to USD 282 million in...
Vifor Fresenius Medical Care Renal Pharma and OPKO Health Enter into Agreement for OPKO's RAYALDEE®
May 09, 2016 01:05 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Vifor Fresenius Medical Care Renal...
Vifor Fresenius Medical Care Renal Pharma and Relypsa announce Submission of Marketing Authorisation Application Requesting European Approval of Patiromer for treatment of hyperkalemia
April 25, 2016 01:11 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
Vifor Fresenius Medical Care Renal...
Swissmedic lässt Akynzeo® (Netupitant/Palonosetron) zur Prävention von Chemotherapie-induzierter Übelkeit und Erbrechen (CINV) für die Schweiz zu
December 15, 2015 01:20 ET
|
Vifor Pharma Ltd.
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px; border-color:black;}
- Erste Fixkombination, die in zwei...